59
Participants
Start Date
August 7, 2020
Primary Completion Date
April 29, 2024
Study Completion Date
April 29, 2024
IMP4297(senaparib)
The dose levels will be escalated following a modified 3+3 dose escalation scheme.
National Taiwan University Hospital, Taipei
Chang Gung Medical Foundation Linko, Taoyuan District
China Medical University Hospital, Taichung
National Cheng Kung University Hospital, Tainan City
Blacktown Hospital, Blacktown
Border Medical Oncology, Albury
Orange Hospital, Orange
Chungbuk National University Hospital, Cheongju-si
Peninsula Health Frankston Hospital, Frankston
The Catholic university of Korea, st. Vincent's Hospital, Gyeonggi-do
Sarah Cannon Research Institute - Tennessee Oncology, Tennessee City
Mark H. Zangmeister Center, Columbus
Gabrail Cancer Researh Center, Canton
GenHarp Clinical Solutions, Evergreen Park
Chi Mei Medical Center, Tainan City
Beijing Cancer Hospital, Beijing
Jilin Cancer Hospital, Jilin
Fudan University Shanghai Cancer Center, Shanghai
Hubei Cancer Hospital, Wuhan
Yonsei university health system, Severance Hospital, Seoul
Asan Medical Center, Seoul
Lead Sponsor
Impact Therapeutics, Inc.
INDUSTRY